Search results for "t effector memory cells"

showing 1 items of 1 documents

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab

2015

International audience; Natalizumab (NTZ), a monoclonal antibody recognizing the alpha4 integrin chain, has been approved for the treatment of active multiple sclerosis, but expose to the onset of a rare side effect, progressive multifocal leukoencephalopathy (PML). Estimating the individual risk of PML in NTZ-treated patients is a major challenge, and therapeutic strategies are mainly guided by the overall PML risk assessed by identified risk factors: JC virus (JCV) seropositivity, treatment duration (with peak incidence after 24 months), and the previous use of immunosuppressive therapies. Given that this stratification does not yet allow a precise individual prediction of PML, other pred…

lcsh:Immunologic diseases. Allergy[SDV.IMM] Life Sciences [q-bio]/ImmunologySide effectmedicine.drug_classvirusesImmunologyJC virusReview Articlerisk stratificationCD11aJC virusmultiple sclerosismedicine.disease_causeMonoclonal antibodyCD49dprogressive multifocal leukoencephalopathyNatalizumabeffector memory T-cellst effector memory cellsImmunology and AllergyMedicineselectinPMLbusiness.industryMultiple sclerosisProgressive multifocal leukoencephalopathyvirus diseasesmedicine.disease3. Good healthJCVImmunologySelectins[SDV.IMM]Life Sciences [q-bio]/Immunologylcsh:RC581-607businessmedicine.drugFrontiers in Immunology
researchProduct